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Abstract 
Background: Talazoparib (1 mg/day) exhibited promising efficacy and safety in patients with 
advanced breast cancer during ABRAZO (NCT02034916); this study evaluated patient-reported 
outcomes (PROs). 
Patients and Methods: ABRAZO is a 2-cohort, 2-stage, phase 2 study of talazoparib in 
patients with advanced breast cancer following a response to prior platinum-based therapy 
(cohort 1 [C1], n = 49) or ≥3 platinum-free cytotoxic-based regimens (cohort 2 [C2], n = 35). 
PROs were assessed on day 1 (baseline), every 6 weeks for an initial 24 weeks, and every 12 
weeks thereafter until progression, using the European Organisation for Research and 
Treatment of Cancer Quality of Life Questionnaire Core 30 (QLQ-C30) and its breast cancer 
module, QLQ-BR23.  
Results: GHS/QoL was maintained from baseline across all time points for both C1 and C2. For 
C1 and C2, median time to deterioration (TTD) of GHS/QoL (95% confidence interval [CI]) was 
2.8 (2.1, 3.0) and 5.5 (4.2, 5.7) months, respectively. Median TTD for all QLQ-C30 functional 
scales for C1 and C2 ranged 2.1–3.1 months and 4.2–5.6 months, respectively; median TTD for 
all QLQ-BR23 symptoms scales ranged 2.6–4.0 months and 4.2–5.6 months, respectively. 
There were no statistically significant differences in estimated overall mean change from 
baseline in the GHS/QoL scale for both cohorts (C1: –2.6 [95% CI, –7.8, 2.5]; C2: 1.2 [95% CI, 
–5.5, 8.0]). Significant overall improvements in the breast symptoms, arm symptoms, and the 
future perspective of patients in C1 and C2 were observed despite the statistically significant 
and clinically meaningful overall deterioration among patients regarding their role functioning (in 
C1) and dyspnea symptoms (in C2). 
 
Conclusions: Despite the statistically significant and clinically meaningful overall deterioration 
among patients regarding their role functioning (in C1) and dyspnea symptoms (in C2), patients 
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in both C1 and C2 reported significant overall improvements in their breast symptoms, arm 
symptoms, and future perspective, and their GHS/QoL was maintained from baseline. 
 
Keywords 
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Quality of life; BRCA1; BRCA2  
 
1. Introduction  
 
Breast cancer susceptibility genes, BRCA1 and BRCA2 (BRCA1/2), are essential components 
in DNA double-strand break repair. Approximately 5% of unselected patients with breast cancer 
carry a germline BRCA1/2 (gBRCA1/2) mutation [1]. Cancer cells with a BRCA1/2 mutation are 
deficient in homologous recombination DNA repair, and the inhibition of poly(ADP-ribose) 
polymerase (PARP) results in synthetic lethality in these cells. This susceptibility has been 
exploited in BRCA-mutated tumors with the clinical development of several PARP inhibitors for 
a range of cancers [2]; in two clinical trials that investigated ovarian cancer patients treated with 
PARP inhibitors, no significant detrimental effect on their quality of life (QoL) was observed [3-
5]. Efficacy and safety of the PARP inhibitor talazoparib as a single agent in patients with locally 
advanced or metastatic breast cancer with a gBRCA mutation were studied in a phase 2 clinical 
trial (ABRAZO, NCT02034916); primary results demonstrated 21%–37% objective response 
rates (ORR) by independent radiology facility (IRF); additional overall ORR by IRF have also 
been reported (triple-negative breast cancer, hormone receptor positive/human epidermal 
growth factor receptor 2 positive/negative: 26% and 29%, respectively; gBRCA1, gBRCA2 
mutation: 23% and 33%, respectively) [3].  
Therapies that control disease are expected to maintain QoL; however, drug-related 
toxicity, even with molecularly targeted treatments, could diminish QoL among patients with 
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advanced breast cancer [7]. The maintenance of QoL is particularly important in the advanced 
breast cancer setting, where treatment is palliative, not curative.  
Hence, when evaluating new treatments, it is imperative to evaluate the quality of the 
time gained by delaying disease progression via patient-reported outcomes (PROs). Here we 
report detailed PROs from the ABRAZO study and determine the effects of talazoparib 
treatment on QoL in patients with locally advanced or metastatic breast cancer carrying a 
gBRCA mutation who have received prior platinum-based therapy or ≥3 platinum-free cytotoxic-
based regimens. 
 
2. Methods 
2.1 Study design and participants 
 
This open-label, two-cohort, two-stage, international, phase 2 study assessed talazoparib in 
patients with locally advanced or metastatic breast cancer with a deleterious or a suspected 
deleterious gBRCA1/2 mutation. Cohort 1 included those with a documented complete response 
or a partial response to a prior platinum-containing regimen for metastatic disease, with no 
disease progression on or within 8 weeks of the last dose of platinum therapy. Cohort 2 had 
received ≥3 prior cytotoxic chemotherapy regimens for metastatic disease and no prior platinum 
therapy for metastatic disease. Patients received continuous oral talazoparib 1 mg daily. A 
detailed study design was previously presented [6].  
 
2.2 PRO assessments 
PROs were assessed using the European Organisation for Research and Treatment of Cancer 
(EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30, version 3.0) and its breast cancer 
module (QLQ-BR23). 
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Assessments were performed at baseline (7 days prior to cycle 1 day 1) and whenever 
tumor assessments were performed (ie, every 6 weeks for the initial 24 weeks from the date of 
cycle 1 day 1, then every 12 weeks or sooner if progression was clinically suspected, and at any 
unscheduled tumor assessment; always ±7 days). Patients were to complete these instruments 
in the clinic prior to having any tests and any discussion of their progress with healthcare site 
personnel.  
EORTC QLQ-C30 is a 30-item questionnaire comprising five multi-item functional 
subscales, three multi-item symptom scales, a global health status (GHS)/QoL subscale, and 
six single-item symptom scales assessing other cancer-related symptoms. The questionnaire 
includes 4-point Likert scales, with responses from “not at all” to “very much” to assess 
functioning and symptoms, and two 7-point Likert scales for GHS/QoL [8]. EORTC QLQ-BR23 
is a 23-item breast cancer–specific companion module to the EORTC QLQ-C30 that comprises 
four functional scales and four symptom scales. Responses to all items are converted to a 0–
100 scale using a standard scoring algorithm [9]. For functional and GHS/QoL scales, higher 
scores represent a better level of functioning and QoL (a negative change from baseline reflects 
deterioration, and a positive change reflects improvement). For symptom scales, a higher score 
represents higher symptoms severity (a negative change reflects improvement, and a positive 
change reflects deterioration).  
 
2.3 Statistical analyses 
All PRO analyses included PRO-evaluable patients, defined as those in the intention-to-treat 
(ITT) population with a baseline and at least one postbaseline assessment before the end of 
study treatment. Completion rates were summarized by assessment time points. Summary 
statistics results are presented by cohort at baseline and at assessment time points.  
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We performed prespecified analyses of change from baseline in GHS/QoL, functional 
(QLQ-C30 and QLQ-BR23), and symptom (QLQ-C30 and QLQ-BR23) scales, and time to 
deterioration (TTD) on the GHS/QoL, functional (QLQ-C30), and symptom (QLQ-BR23) scales. 
For each cohort, statistical significance was interpreted using 95% confidence intervals (CIs) of 
the average change from the baseline score. Clinically meaningful change was defined as a 10-
point or greater change from baseline in GHS/QoL, functional, and symptom score [10]. The 
TTD on GHS/QoL and functional scales was determined using Kaplan–Meier (KM) survival 
analysis methods from baseline to the first occurrence of a 10-point or greater decrease in 
functional score, disease progression, or death (whichever occurred first). Similarly, TTD on the 
breast cancer–specific symptom scale was determined using KM survival analysis methods 
from baseline to the first occurrence of a 10-point or greater increase in symptom score, disease 
progression, or death (whichever occurred first). Survival analyses methods included the KM 
approach for estimating the medians and percentiles and the Brookmeyer and Crowley method 
for computing 95% CIs. 
The post hoc overall mean change from the baseline score was estimated based on a 
longitudinal mixed-effect random-intercept, random-slope model with variables of treatment, 
time, treatment by time, and baseline used as covariates. A restricted maximum likelihood 
method assuming an unstructured covariance matrix was used. All analyses were conducted 
using Statistical Analysis System software (SAS Institute, Cary, NC, USA). All P values are two-
sided, unless stated otherwise. 
 
Results 
3.1 Patients 
Between May 2014–February 2016, 84 patients were enrolled and included in the ITT 
population. Further information on the ITT population are available in Supplementary Fig. S1 
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and Table S1. The median age was 50 years for cohort 1 and 52 years for cohort 2. The median 
number of prior cytotoxic regimens received for advanced breast cancer was two for cohort 1 
and four for cohort 2.  
Up to week 36, when there were still more than 10 eligible patients, compliance was 
≥53% in cohort 1 and ≥45% in cohort 2 (Supplementary Tables S2 and S3).  
 
3.2 GHS/QoL 
Baseline mean GHS/QoL scores were moderately high in both cohorts (Table 1). Baseline 
scores in the study were within range of published normative reference values (Table 1) [11]. 
Based on interpretation of the 95% CIs for the change from baseline analysis, GHS/QoL scores 
were maintained from baseline to the end of treatment across all time points within each cohort 
(Supplementary Fig. S2 and S3; Table S4).  
Based on the repeated-measures mixed-effect model, there was no statistically 
significant overall change from baseline in GHS/QoL scores for either cohort (Table 2). The 
median TTD on the GHS/QoL scale was 2.8 (95% CI, 2.1, 3.0) months and 5.5 (95% CI, 4.2, 
5.7) months for cohort 1 and cohort 2, respectively (Supplementary Table S5). See Fig. 1 for 
KM curves for TTD on the GHS/QoL scale for cohorts 1 and 2.  
 
3.3 Functional scales (QLQ-C30) 
Baseline functional scale scores indicated high functional levels in both cohorts and were 
generally consistent with normative reference values (Table 1). Based on interpretation of the 
95% CIs, the changes from baseline within cohort 1 (Supplementary Fig. S2) indicated 
statistically significant deterioration in role functioning (at end of treatment) and emotional 
functioning (week 12). 
The changes from baseline within cohort 2 (Supplementary Fig. S3) indicated 
statistically significant improvement in physical functioning (weeks 12 and 24), role functioning 
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(week 24), emotional functioning (week 12), and social functioning (weeks 18 and 24). No 
additional statistically significant change was observed for any other functional scale at any 
other assessment visit for cohorts 1 or 2.  
Based on the repeated-measures mixed-effect model, there was a statistically significant 
and a clinically meaningful deterioration in the estimated mean overall change from baseline in 
role functioning for cohort 1 (Table 2). For cohort 2, there were statistically significant but not 
clinically meaningful improvements in the estimated mean overall change from baseline in role 
functioning and social functioning (Table 2). 
The median TTD on all functional scales ranged from 2.1–3.1 months for cohort 1, and 
from 4.2–5.6 months for cohort 2 (Supplementary Table S5). 
 
3.4 Symptom scales (QLQ-C30) 
The mean baseline symptom scale scores indicated low symptom severity in both cohorts and 
were generally consistent with the reference values (Table 1), although constipation tended to 
be lower and diarrhea tended to be higher than the reference values in cohort 1.  
Based on the interpretation from the 95% CIs, in cohort 1, there was a statistically 
significant deterioration from baseline in fatigue (weeks 6 and 12). There was a statistically 
significant improvement in dyspnea (week 24; Supplementary Fig. S2). 
In cohort 2, statistically significant improvements were observed in fatigue (week 24), 
nausea/vomiting (week 18), and pain (week 24; Supplementary Fig. S3). No additional 
statistically significant change was observed for any other symptom scale at any other 
assessment visit for cohorts 1 and 2.   
Based on the repeated-measures mixed-effect model, there was a statistically significant 
deterioration in the estimated mean overall change from baseline in fatigue for cohort 1 (Table 
2); there were statistically significant but not clinically meaningful improvements in the estimated 
mean overall change from baseline in diarrhea (Table 2). In cohort 2, there were statistically 
10 
 
significant but not clinically meaningful improvements in the estimated mean overall change 
from baseline in nausea/vomiting, pain, and insomnia (Table 2). There was a statistically 
significant and a clinically meaningful deterioration in the estimated mean overall change from 
baseline in dyspnea in cohort 2.  
 
3.5 Functional scales (QLQ-BR23) 
Both cohorts tended to have numerically lower scores than normative reference values within all 
four scales, with the exception of sexual enjoyment in cohort 2, which was comparable to the 
reference value (Table 1). The sample sizes for sexual enjoyment were smaller than those for 
other scales because patients were asked to respond to this question only if they responded 
that they were sexually active in a previous question. 
Based on interpretation of the 95% CIs, the change from baseline within cohort 1 
indicated statistically significant improvements in body image (week 6), sexual functioning (week 
18), sexual enjoyment (week 36), and future perspective (week 24; Supplementary Fig. S2). 
The change from baseline within cohort 2 indicated statistically significant improvements 
in future perspective (weeks 6 and 12; Supplementary Fig. S3). No additional statistically 
significant change was observed for any other functional scale at any other assessment visit for 
cohorts 1 and 2.    
Based on the repeated-measures mixed-effect model, there was a statistically significant 
and a clinically meaningful improvement in the estimated mean overall change from baseline in 
future perspective and a statistically significant improvement in sexual functioning in cohort 1 
(Table 2). There were statistically significant but not clinically meaningful improvements in the 
estimated mean overall change from baseline in sexual enjoyment and future perspective in 
cohort 2 (Table 2).  
11 
 
 
3.6 Symptom scales (QLQ-BR23) 
The sample sizes for the “upset by hair loss” symptom scale are much lower than those for the 
other symptom scales because this question was to be answered only if the patient experienced 
hair loss. All values from both cohorts were comparable to the reference values, with the 
exception of “upset by hair loss,” which was much higher in both cohorts than the reference 
values. (Table 1) 
Based on interpretation of the 95% CIs, in cohort 1, a statistically significant deterioration 
in systemic therapy side effects was observed at the end of treatment. There were statistically 
significant improvements in breast symptoms and arm symptoms (week 6; Supplementary Fig. 
S2). 
In cohort 2, a statistically significant improvement in breast symptoms was observed (weeks 6 
and 18). In addition, a statistically significant improvement in arm symptoms was observed 
(week 48; Supplementary Fig. S3). No additional statistically significant change was observed 
for any other symptom scale at any other assessment visit for cohorts 1 and 2.   
Based on the repeated-measures mixed-effect model, there were statistically significant 
improvements in the estimated mean overall change from baseline in breast symptoms and arm 
symptoms for both cohorts (Table 2).  
The median TTD across all of the symptom scales ranged from 2.6–4.0 months in cohort 
1 and from 4.2–5.6 months in cohort 2 (Supplementary Table S5).  
 
4. Discussion 
Preserving QoL in patients with advanced breast cancer is critical, especially when testing the 
efficacy of new therapies. Recently published European Society for Medical Oncology (ESMO) 
Magnitude of Clinical Benefit Scale guidance emphasized the importance of a holistic 
assessment of the value of medicine that includes PROs in addition to efficacy and safety [12]. 
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Presented herein are the first-ever detailed PROs regarding talazoparib in patients with 
advanced breast cancer. We show that the encouraging efficacy achieved with talazoparib is 
accompanied by maintaining patient-reported GHS/QoL.  
The recent fourth European School of Oncology-ESMO international consensus 
guidelines for advanced breast cancer recommended a platinum regimen (if not previously 
administered and no suitable clinical trial is available) for BRCA-associated triple-negative or 
endocrine-resistant metastatic breast cancer previously treated with an anthracycline with or 
without a taxane (in the adjuvant and/or metastatic setting) [13, 14]. This recommendation was 
based on Tutt et al [14] who reported that carboplatin was associated with significantly better 
objective tumor response rates than docetaxel among patients with triple-negative breast cancer 
and with gBRCA1/2 mutations. Nevertheless, it is important to also consider the potential 
detrimental QoL effects of platinum-based chemotherapy. Amadori et al [15] found that patients 
with advanced breast cancer treated with pemetrexed and carboplatin had significantly greater 
deterioration in GHS/QoL scores than those treated with vinorelbine and gemcitabine.  
Patients receiving treatment for advanced breast cancer can be symptomatic, with 
significant impairment in daily activity and/or work productivity [16]. Because disease 
progression may negatively affect QoL, delaying progression could delay QoL deterioration, 
barring any significant detrimental treatment-related toxicity. A large proportion of patients with 
advanced breast cancer with bone metastases experience significant pain and have a high 
incidence of skeletal-related events [17]. Our results showed no significant deterioration of pain 
symptoms across all time points in cohort 1, and encouraging, statistically significant and 
clinically meaningful improvement in pain symptoms in cohort 2 at week 24. Such results further 
support the positive risk–benefit profile of talazoparib and show that talazoparib does not 
impose toxicities that interfere with patient GHS/QoL. However, it should be noted that a 
limitation of our study is the small sample size analyzed because of patient dropout.  
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5. Conclusion 
The impact of living with incurable advanced breast cancer may go unrecognized by 
healthcare professionals. The unpredictable course of advanced breast cancer often leaves 
patients feeling vulnerable and distressed, with no sense of control over their future [18]. 
GHS/QoL was maintained from baseline in both cohorts; in addition, significant overall 
improvements in the breast symptoms, arm symptoms, and the future perspective of patients in 
both cohorts were observed despite the statistically significant and clinically meaningful overall 
deterioration among patients regarding their role functioning (cohort 1) and dyspnea symptoms 
(cohort 2). Published positive PRO results from another PARP inhibitor [19] and recently 
presented positive PRO results from a randomized, two-arm, phase 3 trial (NCT01945775) that 
compared talazoparib with physician’s choice of cytotoxic chemotherapy (PCT) in patients with 
gBRCA1/2 advanced breast cancer (talazoparib vs PCT for ORR [63% vs 27%, respectively] 
and median progression-free survival [8.6 vs 5.6 months, respectively]) [20] provide very 
encouraging outlooks regarding the effects of PARP inhibitors on QoL of patients with advanced 
breast cancer.  
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Table 1. Baseline EORTC QLQ-C30 and QLQ-BR23 scores and reference values (PRO 
analysis set)a 
EORTC domain/scale 
Cohort 1 (n = 49) Cohort 2 (n = 35) 
Reference 
values
b,8
 
N
a
 Mean (95% CI) N
a
 Mean (95% CI) Mean (SD) 
QLQ-C30 GHS/QoL
c
 
GHS/QoL 47 65.1 (59.9, 70.2) 34 63.2 (56.6, 69.9) 60.2 (25.5) 
QLQ-C30 functional scales
c
 
Physical functioning 47 80.6 (75.7, 85.4) 35 79.4 (74.3, 84.6) 81.6 (18.7) 
Role functioning 47 75.5 (68.6, 82.4) 35 70.0 (61.8, 78.2) 67.4 (31.1) 
Emotional functioning 47 73.2 (66.3, 80.2) 34 72.8 (66.1, 79.5) 65.9 (24.6) 
Cognitive functioning 47 85.8 (80.7, 90.9) 34 87.3 (81.5, 93.0) 80.5 (23.2) 
Social functioning 47 72.7 (64.8, 80.6) 34 74.0 (66.3, 81.8) 74.2 (28.4) 
QLQ-C30 symptom scales
d
 
Fatigue 47 35.0 (27.9, 42.1) 35 36.3 (29.1, 43.6) 36.3 (27.0) 
Nausea/vomiting 47 11.3 (6.3, 16.4) 35 11.4 (5.3, 17.6) 10.3 (19.7) 
Pain 46 26.4 (18.5, 34.4) 35 32.4 (23.0, 41.8) 30.9 (29.6) 
Dyspnea 47 24.8 (17.3, 32.3) 35 21.9 (13.6, 30.2) 20.4 (28.2) 
Insomnia 47 31.2 (22.2, 40.2) 35 32.4 (21.5, 43.3) 33.1 (32.6) 
Appetite loss 47 19.1 (11.3, 27.0) 35 18.1 (10.1, 26.1) 21.7 (31.0) 
Constipation
c
 47 9.2 (3.9, 14.5) 34 20.6 (11.5, 29.6) 19.2 (28.8) 
Diarrhea
c
 47 10.6 (4.5, 16.8) 34 4.9 (0.7, 9.1) 5.8 (15.2) 
QLQ-BR23 functional scales
c
 
Body image 46 64.5 (55.2, 73.8) 35 67.5 (57.7, 77.2) 81.9 (22.6) 
Sexual functioning 44 14.0 (8.6, 19.5) 33 15.7 (9.1, 22.3) 19.2 (23.2) 
Sexual enjoyment 16 52.4 (32.8, 71.9) 12 33.3 (17.7, 49.0) 55.1 (25.6) 
Future perspective 47 38.3 (28.3, 48.3) 35 34.3 (22.7, 45.9) 47.6 (34.1) 
QLQ-BR23 symptom scales
d
 
Systemic therapy side effects 47 16.7 (12.4, 20.9) 35 15.2 (11.4, 19.0) 15.8 (14.3) 
Breast symptoms 47 15.9 (9.9, 21.9) 35 18.5 (10.0, 26.9) 17.6 (16.7) 
Arm symptoms 47 22.5 (15.4, 29.5) 35 19.7 (9.4, 30.0) 21.0 (21.1) 
Upset by hair loss 8 58.3 (33.6, 83.0) 6 27.8 (13.5, 42.1) 5.3 (19.3) 
Abbreviations: CI, confidence interval; EORTC, European Organisation for Research and 
Treatment of Cancer; GHS, global health status; PRO, patient-reported outcome; QLQ-
BR23, Quality of Life Questionnaire breast cancer module; QLQ-C30, Quality of Life 
Questionnaire Core 30; QoL, quality of life; SD, standard deviation. 
a PRO-evaluable population is defined as all patients who have completed ≥1 PRO 
question at baseline and ≥1 PRO question postbaseline. 
b Reference values for patients with recurrent/metastatic across all lines of treatment are 
shown (reference 8). 
c Larger values better.  
d Larger values worse. 
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Table 2. Estimated mean overall change from baseline (mixed-effects model) 
 
Cohort 1 Cohort 2 
Domain/scale Overall (95% CI) Overall (95% CI) 
EORTC QLQ-C30 GHS/QoL (positive changes correspond to better outcome) 
GHS/QoL –2.6 (–7.8, 2.5) 1.2 (–5.5, 8.0) 
EORTC QLQ-C30 functional scales (positive changes correspond to better outcome) 
Physical functioning –3.2 (–7.6, 1.3) 1.3 (–2.0, 4.6) 
Role functioning –11.0 (–19.0, –2.9) 6.9 (3.1, 10.7) 
Emotional functioning –5.4 (–12.0, 1.2) 1.8 (–3.3, 6.9) 
Cognitive functioning –4.5 (–9.2, 0.2) 0.1 (–3.6, 3.9) 
Social functioning –0.9 (–8.0, 6.2) 8.3 (4.3, 12.3) 
EORTC QLQ-C30 symptoms scales (negative changes correspond to better outcome) 
Fatigue 7.6 (2.1, 13.0) –3.9 (–8.7, 0.9) 
Nausea/vomiting 
 
NE –4.3 (–7.1, –1.6) 
Pain 
 
NE –8.2 (–14.4, –2.0) 
Dyspnea –0.9 (–6.8, 5.0) 10.3 (1.3, 19.2) 
Insomnia –0.6 (–7.7, 6.6) –7.2 (–12.9, –1.5) 
Appetite loss 1.3 (–4.3, 7.0) –0.8 ( –7.6, 6.0) 
Constipation 
 
NE –1.5 (–7.0, 3.9) 
Diarrhea –5.4 (–9.4, –1.4) 1.6 (–3.4, 6.6) 
EORTC QLQ-BR23 functional scales (positive changes correspond to better outcome) 
Body image 5.6 (–0.2, 11.4) 3.6 (–2.7, 10.0) 
Sexual functioning 5.6 (0.9, 10.3) –0.3 (–5.8, 5.1) 
Sexual enjoyment 
 
NE 9.1 (1.8, 16.5) 
Future perspective 11.1 (1.9, 20.2) 9.9 (1.8, 18.0) 
EORTC QLQ-BR23 symptoms scales (negative changes correspond to better outcome) 
Systemic therapy side effects 0.6 (–2.6, 3.9) 0.9 ( –2.1, 3.8) 
Breast symptoms –6.6 (–11.1, –2.2) –8.7 (–13.0, –4.4) 
Arm symptoms –6.6 (–12.6, –0.6) –4.4 (–8.0, –0.8) 
Upset by hair loss 
 
NE –16.7 (–67.4, 34.1) 
Abbreviations: CI, confidence interval; EORTC, European Organisation for Research and Treatment of 
Cancer; GHS, global health status; NE, not estimated; QLQ-BR23, Quality of Life Questionnaire breast 
cancer module; QLQ-C30, Quality of Life Questionnaire Core 30; QoL, quality of life. 
Notes: Data in the table are color coded as follows: dark orange = clinically meaningful and statistically 
significant (deterioration); light orange = statistically significant (deterioration); green = clinically 
meaningful and statistically significant (improvement); light green = statistically significant (improvement). 
 
 
